raw materials – Page 10

Analytical method sensitivity questioned during regulatory inspection – preventing product recall

Addressing Analytical Method Sensitivity Concerns Identified During Regulatory Inspections In recent regulatory inspections, questions surrounding the sensitivity of analytical methods have led to increased scrutiny of manufacturing processes, particularly in…

FIFO not followed during inventory reconciliation – GMP storage compliance requirements

Investigating Non-Compliance with FIFO During Inventory Reconciliation in GMP Storage In the pharmaceutical manufacturing environment, strict compliance with Good Manufacturing Practices (GMP) is essential, particularly when it comes to inventory…

Segregation controls inadequate during investigation – CAPA and system strengthening

Strengthening Segregation Controls During Investigations: A Playbook for Pharma Professionals In the pharmaceutical manufacturing landscape, inadequate segregation controls during investigations can lead to significant compliance issues and potential product contamination.…

Sampler training deficiency during deviation investigation – GMP expectations for material sampling

Addressing Issues with Sampler Training Deficiencies in Deviation Investigations In pharmaceutical manufacturing, the integrity of raw material sampling is critical to maintaining product quality and regulatory compliance. A common issue…

Traceability records incomplete during investigation – CAPA and system strengthening

Addressing Incomplete Traceability Records during Investigations: A Comprehensive Guide In the pharmaceutical manufacturing landscape, maintaining rigorous traceability records is critical for ensuring quality and regulatory compliance. The challenge of incomplete…

Non-representative sampling detected during regulatory inspection – CAPA to prevent recurrence

Addressing Non-Representative Sampling Issues Detected During Regulatory Audits During recent regulatory inspections, instances of non-representative sampling have raised significant concerns regarding compliance and quality assurance in pharmaceutical manufacturing. These findings…

Material mix-up incident reported during investigation – CAPA and system strengthening

Actionable Playbook for Managing Material Mix-Up Incidents in Pharma Material mix-up incidents present significant challenges in pharmaceutical manufacturing, leading to potential risks in product quality and patient safety. The need…

Cross-contamination during sampling during deviation investigation – root cause analysis for sampling failures

Analysis of Cross-Contamination During Sampling in Deviation Investigations Cross-contamination during sampling is an issue of significant concern in pharmaceutical manufacturing. This problem not only jeopardizes product quality but can also…

Segregation controls inadequate during warehouse operations – preventing repeat mix-up events

Effective Strategies for Addressing Inadequate Segregation Controls During Warehouse Operations In pharmaceutical manufacturing, proper segregation controls are critical to ensuring material traceability and preventing mix-up events. However, inadequate segregation controls…

Sampling plan not risk-based during internal audit – preventing false OOS results

Assessing and Addressing Non-Risk-Based Sampling Plans during Internal Audits In pharmaceutical manufacturing, the integrity of raw material sampling plans is critical to achieving compliance and maintaining product quality. However, when…

Reconciliation discrepancies during dispensing – inspection defense documentation

Addressing Reconciliation Discrepancies during Dispensing: A Comprehensive Playbook In pharmaceutical manufacturing, reconciliation discrepancies during dispensing can lead to significant production delays, quality issues, and regulatory scrutiny. Timely identification and resolution…

Improper sample storage during incoming material receipt – CAPA to prevent recurrence

Addressing Improper Sample Storage During Incoming Material Receipt: Comprehensive CAPA Measures In the pharmaceutical manufacturing landscape, the integrity of raw materials is paramount. Improper sample storage during incoming material receipt…